Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine
Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine
复制标题
DOI：
10.1377/hlthaff.2017.0890
复制
发表时间：
2017-12-01
期刊：
影响因子：
9.7
通讯作者：
Saloner, Brendan
中科院分区：
文献类型：
--
作者：
Krawczyk, Noa;Picher, Caroline E.;Saloner, Brendan
在美国刑事司法系统中，阿片类药物使用障碍、过量使用和其他不良后果的发生率很高。扩大治疗是应对阿片类药物流行的一项关键战略，但对于刑事司法系统是否向人们提供最高标准的治疗：使用阿片类药物激动剂疗法美沙酮或丁丙诺啡，人们知之甚少。我们使用2014年国家治疗事件数据集的数据来检查涉及阿片类药物使用障碍专科治疗的司法人员中激动剂治疗的使用情况。司法推荐的客户中只有4.6%接受了激动剂治疗，而其他来源推荐的客户中有40.9%接受了激动剂治疗。在所有刑事司法来源中，法院和转移项目最不可能将人们转介到激动剂治疗。我们的研究结果表明，为寻求阿片类药物使用障碍治疗的司法相关人员提供有效的循证护理的机会正在错过。
People in the US criminal justice system experience high rates of opioid use disorder, overdose, and other adverse outcomes. Expanding treatment is a key strategy for addressing the opioid epidemic, but little is known about whether the criminal justice system refers people to the highest standard of treatment: the use of the opioid agonist therapies methadone or buprenorphine. We used 2014 data from the national Treatment Episode Data Set to examine the use of agonist treatment among justice-involved people referred to specialty treatment for opioid use disorder. Only 4.6 percent of justice-referred clients received agonist treatment, compared to 40.9 percent of those referred by other sources. Of all criminal justice sources, courts and diversionary programs were least likely to refer people to agonist treatment. Our findings suggest that an opportunity is being missed to promote effective, evidence-based care for justice-involved people who seek treatment for opioid use disorder.